BioLineRx (BLRX) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Jones Trading Reiterates Hold Rating on BioLineRx (BLRX)
May 28, 2025 8:59 AM EDTJones Trading analyst Justin Walsh reiterated a Hold rating on BioLineRx (NASDAQ: BLRX).
The analyst comments "APHEXDA will provide a steady stream of royalties that support earlier stage development of assets expected to be in-licensed in 2025-2026, most likely in the oncology and/or... More



